+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Acadia Pharmaceuticals Inc  - logo

Acadia Pharmaceuticals is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease, Phase II trial for the treatment of schizophrenia and Phase II study for the treatment of Alzheimer's disease. The company was founded in 1993 and is headquartered in San Diego, California.

Schizophrenia - Pipeline Review, H2 2019 - Product Thumbnail Image

Schizophrenia - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 373 Pages
From
Markets at a Glance: Pharmaceuticals - Product Thumbnail Image

Markets at a Glance: Pharmaceuticals

  • Report
  • May 2019
  • 115 Pages
From
From
From
From
Depression - Pipeline Review, H1 2020 - Product Thumbnail Image

Depression - Pipeline Review, H1 2020

  • Drug Pipelines
  • March 2020
  • 668 Pages
From
From
From
COPD: Pipeline Assessment and Insights - Product Thumbnail Image

COPD: Pipeline Assessment and Insights

  • Report
  • April 2018
  • 100 Pages
From
From
From
From
From
Psychosis Global Clinical Trials Review, H2, 2019 - Product Thumbnail Image

Psychosis Global Clinical Trials Review, H2, 2019

  • Clinical Trials
  • December 2019
  • 290 Pages
From
From
From
Loading Indicator
adroll